Skip to content

Bioalmanac

Selank

Tuftsin analogue · TP-7

Approved for another indication

Status reviewed 12 Aug 2026

A seven-amino-acid peptide developed in Russia and used there for anxiety. Nasal rather than injected, and the sibling compound to Semax.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. A nasal solution is entered repeatedly over weeks, so bacteriostatic rather than sterile water matters here.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described nasal dose250–500 mcgOnce to three times daily, split between nostrilsCommunity practice

When to stop

  • Persistent nasal pain, bleeding or crusting.
  • Any allergic response: rash, facial swelling or difficulty breathing. Seek urgent care.
  • Worsening mood, or any thoughts of self-harm. Anxiety treatments can move mood in unexpected directions and this one has no independent safety monitoring behind it.
  • Any new neurological symptom.

Approved and used clinically in Russia as an anxiolytic. Not approved in the United States, the EU or the UK, where material sold under this name is an unapproved substance with no manufacturing standard behind it.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/selank

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.